Onset of action of budesonide/formoterol Spiromax^® compared with budesonide/formoterol Turbuhaler^® in patients with COPD

详细信息    查看全文

• 作者：Mario Cazzola ; ^{mario.cazzola@uniroma2.it" class="auth_mail" title="E-mail the corresponding author} ; Josuel Ora ; Alessanda Di Paolo ; Ermanno Puxeddu ; Luigino Calzetta ; Paola Rogliani
• 关键词：COPD ; Formoterol ; Budesonide ; Spiromax ; Turbuhaler
• 刊名：Pulmonary Pharmacology & Therapeutics
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：39
• 期：Complete
• 页码：48-53
• 全文大小：997 K

文摘

Budesonide/formoterol (BF) is available in two delivery systems, the dry powder inhaler (DPI) Turbuhaler and a pressurized metered dose inhaler (pMDI) for use in patients with asthma or chronic obstructive pulmonary disease (COPD). Spiromax DPI was recently developed as an alternative to Turbuhaler DPI. In the present study, we examined whether there is a difference in the onset of bronchodilatation between BF 320/9 μg delivered by Spiromax and BF 320/9 μg delivered by Turbuhaler in 16 outpatients with stable moderate-to-severe COPD. Our results confirm the rapid onset of action of formoterol when combined with budesonide in patients with COPD and indicate that the onset of bronchodilation induced by BF Spiromax is faster than that elicited by BF Turbuhaler. Furthermore, they show that BF fixed-dose combination does not induce a decrease in SpO₂ or an increase in heart rate in patients with COPD, irrespective of the DPI used to deliver this combination. Given the evidence that both inhalers have an equal safety profile, BF Spiromax offers to prescribers and COPD patients an effective alternative to BF Turbuhaler depending also on their preference, availability and cost.